Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.31 |
| ▸ | BUB1 | O43683 | 1/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18198414 | 0.90 | HSD11B1 (0.40) | HSD11B1ASGR1NFKB1NFKB2RELA | |
| SCHEMBL24207518 | 0.90 | HSD11B1 (0.40) | HSD11B1ASGR1NFKB1NFKB2RELA | |
| SCHEMBL25250119 | 0.86 | HSD11B1 (0.42) | HSD11B1ASGR1NFKB1NFKB2RELA | |
| SCHEMBL25294971 | 0.86 | HSD11B1 (0.42) | HSD11B1ASGR1NFKB1NFKB2RELA | |
| SCHEMBL24588156 | 0.84 | HSD11B1 (0.41) | HSD11B1ASGR1NFKB1NFKB2RELA | |
| SCHEMBL13567986 | 0.81 | HSD11B1 (0.44) | HSD11B1ASGR1NFKB1NFKB2RELA | |
| SCHEMBL16081763 | 0.81 | HSD11B1 (0.44) | HSD11B1ASGR1NFKB1NFKB2RELA | |
| SCHEMBL31236410 | 0.81 | HSD11B1 (0.44) | HSD11B1ASGR1NFKB1NFKB2RELA | |
| SCHEMBL22822421 | 0.81 | HSD11B1 (0.44) | HSD11B1ASGR1NFKB1NFKB2RELA | |
| SCHEMBL24439134 | 0.81 | HSD11B1 (0.44) | HSD11B1ASGR1NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | HSD11B1 4449/4885ASGR1 787/4885HRH3 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.